Effectiveness and safety of salvage therapy in residual retroperitoneal masses in advanced testicular seminoma: A systematic review.

IF 1.3 Q4 UROLOGY & NEPHROLOGY
Maria Paula Gomez, Herney Andres Garcia-Perdomo
{"title":"Effectiveness and safety of salvage therapy in residual retroperitoneal masses in advanced testicular seminoma: A systematic review.","authors":"Maria Paula Gomez, Herney Andres Garcia-Perdomo","doi":"10.1177/03915603261467519","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine the effectiveness and safety of surgery, chemotherapy, or radiotherapy for treating post-chemotherapy residual mass in advanced testicular seminoma in terms of overall survival and progression-free survival.</p><p><strong>Methods: </strong>We conducted a search strategy in MEDLINE (OVID), EMBASE, LILACS, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to nowadays. We assessed the risk of bias and performed this review according to the recommendations of the Cochrane Collaboration and following the PRISMA Statement.</p><p><strong>Results: </strong>Within the included studies, there are 239 patients with germ cell carcinoma, all in an advanced stage of the disease (IIa,IIb, IIc, or III) and where 100% are pure seminomas. The interventions were radiation therapy, immediate resection after the first positive PET, other salvage therapy as second or third chemotherapy for residual masses, and a high dose of chemotherapy and autologous stem cell transplantation. The median progression-free survival in the observation arm was 39.4 months in the very high-risk group and 40 months in the high-risk group, whereas it was not reached for the radiotherapy arm. Also, a new chemotherapy scheme had progression-free survival in a 10-year follow-up of 94.2%. The overall survival for the high-risk group radiotherapy versus observation was not significant (<i>p</i> = 0.47), similar to the very high-risk subgroup (<i>p</i> = 0.42). The reported complications are due to surgical management and chemotherapy toxicity.</p><p><strong>Conclusion: </strong>Evidence on the management of post-chemotherapy residual retroperitoneal masses in advanced seminoma is limited and of low certainty. Available studies are few and heterogeneous, precluding definitive conclusions regarding progression-free or overall survival. Current findings support individualized treatment decisions, while further prospective studies are needed to better define optimal management strategies and long-term outcomes.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603261467519"},"PeriodicalIF":1.3000,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/03915603261467519","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To determine the effectiveness and safety of surgery, chemotherapy, or radiotherapy for treating post-chemotherapy residual mass in advanced testicular seminoma in terms of overall survival and progression-free survival.

Methods: We conducted a search strategy in MEDLINE (OVID), EMBASE, LILACS, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to nowadays. We assessed the risk of bias and performed this review according to the recommendations of the Cochrane Collaboration and following the PRISMA Statement.

Results: Within the included studies, there are 239 patients with germ cell carcinoma, all in an advanced stage of the disease (IIa,IIb, IIc, or III) and where 100% are pure seminomas. The interventions were radiation therapy, immediate resection after the first positive PET, other salvage therapy as second or third chemotherapy for residual masses, and a high dose of chemotherapy and autologous stem cell transplantation. The median progression-free survival in the observation arm was 39.4 months in the very high-risk group and 40 months in the high-risk group, whereas it was not reached for the radiotherapy arm. Also, a new chemotherapy scheme had progression-free survival in a 10-year follow-up of 94.2%. The overall survival for the high-risk group radiotherapy versus observation was not significant (p = 0.47), similar to the very high-risk subgroup (p = 0.42). The reported complications are due to surgical management and chemotherapy toxicity.

Conclusion: Evidence on the management of post-chemotherapy residual retroperitoneal masses in advanced seminoma is limited and of low certainty. Available studies are few and heterogeneous, precluding definitive conclusions regarding progression-free or overall survival. Current findings support individualized treatment decisions, while further prospective studies are needed to better define optimal management strategies and long-term outcomes.

晚期睾丸精原细胞瘤腹膜后残余肿块抢救治疗的有效性和安全性:一项系统综述。
目的:从总生存期和无进展生存期的角度,探讨手术、化疗或放疗治疗晚期睾丸精原细胞瘤化疗后残留肿块的有效性和安全性。方法:我们在MEDLINE (OVID)、EMBASE、LILACS和Cochrane Central Register of Controlled Trials (Central)中进行了自成立至今的检索策略。我们根据Cochrane协作网的建议和PRISMA声明评估偏倚风险并进行本综述。结果:在纳入的研究中,有239例生殖细胞癌患者,均处于疾病晚期(IIa,IIb, IIc或III),其中100%为纯精原细胞瘤。干预措施包括放射治疗,第一次PET阳性后立即切除,其他救助治疗如残余肿块的第二次或第三次化疗,高剂量化疗和自体干细胞移植。观察组的中位无进展生存期在高危组为39.4个月,在高危组为40个月,而放疗组没有达到。此外,一项新的化疗方案在10年随访中的无进展生存率为94.2%。高危组放疗与观察的总生存率无统计学意义(p = 0.47),与高危组相似(p = 0.42)。报告的并发症是由于手术处理和化疗毒性。结论:晚期精原细胞瘤化疗后腹膜后残余肿块的处理证据有限且不确定。现有的研究很少且异质性,排除了关于无进展或总生存期的明确结论。目前的研究结果支持个性化治疗决策,但需要进一步的前瞻性研究来更好地确定最佳管理策略和长期结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Urologia Journal
Urologia Journal UROLOGY & NEPHROLOGY-
CiteScore
0.60
自引率
12.50%
发文量
66
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书